Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce the successful unblinding and data analysis of its pivotal clinical trial for the Felix(TM) System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the WA Life Sciences Broker Meets Biotech event, Perth on 20th March 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the official launch of its first-in-class predictive test for diabetic kidney disease, Promarker(R)D, in Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the publication of results of its landmark study demonstrating the PromarkerD test significantly outperforms the current standard of care tests in predicting future kidney function decline.
Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX:PIQ) (OTCMKTS:PIQLF) is proud to announce that it has opened its US Reference Laboratory and been awarded a Clinical Laboratory Improvement Amendment certificate of registration, as a certified clinical laboratory.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce successful completion of the data lock for the pivotal Felix(TM) clinical trial. This marks a critical milestone in ensuring the accuracy and integrity of the trial data.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics, is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys 2025 Healthcare Forum being held on 4 February 2025.
